

09/634,369

=> d his

(FILE 'HOME' ENTERED AT 22:52:20 ON 10 MAR 2002)

FILE 'REGISTRY' ENTERED AT 22:58:22 ON 10 MAR 2002

L1 0 S 11,12 EPOXYEICOSATRIENOIC ACID/CN
 E 11,12 EPOXYEICOSATRIENOIC ACID/CN
 E 11,12-EPOXYEICOSATRIENOIC ACID/CN
L2 1 S E2
 E EPOXYEICOSATRIENOIC ACID/CN
L3 2 S E3-E4

FILE 'CAPLUS, USPATFULL' ENTERED AT 23:01:18 ON 10 MAR 2002

L4 1 S (L2 OR L3) AND HYPOX?(P) (REOXYGEN? OR RE(2A)OXYGEN?) AND (CEL

=>

FILE 'CAPLUS, USPATFULL' ENTERED AT 23:01:18 ON 10 MAR 2002

=> s (l2 or l3) and hypox?(p)(rexygen? or re(2a)oxygen?) and (cell(4a)death or apoptosis)

L4 1 (L2 OR L3) AND HYPOX?(P)(REOXYGEN? OR RE(2A) OXYGEN?) AND (CELL(4A) DEATH OR APOPTOSIS)

=> d l4 abs ibib kwic 1-2

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

AB Epoxyeicosatrienoic acids (EETs) are products of cytochrome P 450 epoxygenases that have vasodilatory properties similar to endothelium-derived hyperpolarizing factor (EDHF). The cytochrome P 450 isoform CYP2J2 was cloned and identified as a source of EETs in human endothelial cells. Physiol. concns. of EETs or overexpression of CYP2J2 decreased cytolcine-induced endothelial cell adhesion mol. expression and prevented subsequent leukocyte adhesion to the vascular wall by a mechanism involving inhibition of transcription factor NF-.kappa.B and I.kappa.B kinase (IKK). The inhibitory effects of EETs were independent of their membrane hypopolarizing effects suggesting that these mols. play an important non-vasodilatory role in vascular inflammation.

ACCESSION NUMBER: 2001:114981 CAPLUS

DOCUMENT NUMBER: 134:173027

TITLE: Anti-inflammatory actions of cytochrome P450 epoxygenase-derived eicosanoids

INVENTOR(S): Liao, James K.; Zeldin, Darryl

PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA; National Institutes of Health

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010438	A1	20010215	WO 2000-US21744	20000810

W: AU, CA, JP, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1999-148434 P 19990811

US 2000-634369 A2 20000809

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT **Hypoxia**, animal

(prevention of **cell death** from **reoxygenation** following; anti-inflammatory actions of cytochrome P 450 epoxygenase-derived eicosanoids in combination with other agents)

IT **Oxygenation**

(re-, prevention of **cell death** from **hypoxia** and; anti-inflammatory actions of cytochrome P 450 epoxygenase-derived eicosanoids in combination with other agents)

IT **97717-69-6D**, Epoxyeicosatrienoic acid, analogs

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use);

09/634,369

BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(anti-inflammatory actions of cytochrome P 450 epoxygenase-derived
eicosanoids in combination with other agents)

IT 79551-81-8 79551-82-9 81246-84-6 81246-85-7 **81276-02-0**

81276-03-1 81920-20-9 81943-03-5 **97717-69-6**,

Epoxyeicosatrienoic acid 218461-95-1, KMR-IV 87-27 325782-17-0, RKB-V
284-24

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(anti-inflammatory actions of cytochrome P 450 epoxygenase-derived
eicosanoids in combination with other agents)